Business
Rakovina Therapeutics Inc. Appoints Biotechnology Industry Veteran Julie M. Cherrington, PhD to Board of Directors
Rakovina Therapeutics Inc. Appoints Biotechnology Industry Veteran Julie M. Cherrington, ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"\n \n \n \n Rakovina Therapeutics Inc. Appoints Biotechnology Industry Veteran Julie M. Cherrington, PhD to Board of Directors\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n VANCOUVER, BC\n \n ,\n \n April 5, 2021\n \n /CNW/ -\n \n Rakovina Therapeutics Inc. (the \"\n \n \n Company\n \n \n \")\n \n (TSXV: RKV) is pleased to announce the appointment of\n \n Julie M. Cherrington\n \n , PhD to the Company's Board of Directors.\n \n \n \n \n \n \n \n \n \n \"We are delighted to welcome Dr. Cherrington to the Rakovina Therapeutics team,\" said Mr.\n \n Jeffrey Bacha\n \n , Rakovina Therapeutics' executive chairman.  \"The addition of an executive leader with Dr. Cherrington's experience and talent to our Board of Directors will greatly benefit Rakovina Therapeutics as we advance our pipeline of novel anti-cancer agents toward human clinical trials.\"\n \n \n \n Julie M. Cherrington\n \n is an accomplished life science executive with a record of demonstrated success bringing drug candidates into human clinical trials and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products, including the anti-cancer agents SUTENT\n \n ®\n \n and PALLADIA\n \n ®\n \n and the ant-virals VISTIDE\n \n ®\n \n , VIREAD\n \n ®\n \n , and HEPSERA\n \n ®\n \n .\n \n \n Dr. Cherrington has served as President and Chief Executive Officer at several oncology companies, including Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. She has previously served on the Boards of Directors of Chemgenex, Progen, Xenome, and Leading Biosciences. Currently, she serves on the Boards of both QUE Oncology and M...